Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The aim of this retrospective study was to evaluate the cephalometric and occlusal changes of orthodontically treated Class III malocclusion patients.
Methods: The experimental groups comprised 37 Class III patients treated: G1) without (n=19) and G2) with extractions (n=18) . The control group (G3), matched by age and sex with the experimental groups, consisted of 18 subjects with untreated Class III malocclusion. Cephalometric (radiographs) and occlusal (study models) changes were assessed between the beginning (T1) and the end (T2) of treatment. Intergroup comparisons were performed with one-way ANOVA followed by Kruskal-Wallis tests (p< 0.05). Occlusal changes were evaluated by the peer assessment rating (PAR) index (ANOVA and Kruskal-Wallis tests), and the treatment outcomes were evaluated by the Objective Grading System (OGS) (t-tests).
Results: The experimental groups showed a restrictive effect on mandibular anterior displacement and a discrete improvement in the maxillomandibular relationship. Extraction treatment resulted in a greater retrusive movement of the incisors and significant improvements in the overjet and molar relationship in both groups. The PAR indexes were significantly reduced with treatment, and the OGS scores were 25.6 (G1) and 28.6 (G2), with no significant intergroup difference.
Conclusions: Orthodontic treatment of Class III malocclusion patients with fixed appliances improved the sagittal relationships, with greater incisor retrusion in the extraction group. Both the extraction and non-extraction treatments significantly decreased the initial malocclusion severity, with adequate and similar occlusal outcomes of treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510493 | PMC |
| http://dx.doi.org/10.1590/2177-6709.25.4.024-032.oar | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Data harmonization framework for neonatal hypoxic-ischemic encephalopathy studies.
JAMIA Open
October 2025
Fetal-Neonatal Neuroimaging Developmental Science Center, Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Objectives: To develop a data harmonization framework for neonatal hypoxic-ischemic encephalopathy (HIE) studies and demonstrate its suitability for prognostic biomarker development.
Materials And Methods: Variables were first categorized by chronological stages and then by medical topics. We created a dictionary to harmonize variable names and value coding.
Cost-Effectiveness of Obesity Treatments: Glucagon-Like Peptide-1 Receptor Agonists, Endoscopic Sleeve Gastroplasty, and Metabolic/Bariatric Surgery.
J Metab Bariatr Surg
August 2025
Office of Medical Education, Seoul National University College of Medicine, Seoul, Korea.
Obesity represents a major global health challenge, requiring interventions that are both effective and economically sustainable. This review examines the cost-effectiveness of commonly discussed treatment options: glucagon-like peptide-1 receptor agonists (GLP-1 RAs), endoscopic sleeve gastroplasty (ESG), and metabolic/bariatric surgery (MBS). We synthesized evidence from published clinical studies and economic analyses, comparing incremental cost-effectiveness ratios (ICERs) and cost per quality-adjusted life year across obesity severity classes, with particular consideration of implications for Korea's healthcare context.
View Article and Find Full Text PDFNewly diagnosed atrial fibrillation detected by noninvasive screening methods in clinical practice.
Heart Rhythm O2
August 2025
Hospital Privado del Sur & Hospital Regional Español, Bahía Blanca, Argentina.
Background: Patient characteristics and outcomes of newly diagnosed atrial fibrillation (AF) have been investigated in large registries.
Objective: The study aimed to address the role of non-invasive screening tools in diagnosing AF in the Argentinian clinical practice.
Methods: This was an observational retrospective study.
Ferric derisomaltose augments intrinsic skeletal muscle electron transport chain activity in heart failure: A FERRIC-HF II molecular substudy.
Eur J Heart Fail
September 2025
School of Cardiovascular & Metabolic Medicine and Science, James Black Centre, King's College London British Heart Foundation Centre of Excellence, London, UK.
Aims: Skeletal muscle energetic augmentation might be a mechanism via which intravenous iron improves symptoms in heart failure, but no direct measurement of intrinsic mitochondrial function has been performed to support this notion. This molecular substudy of the FERRIC-HF II trial tested the hypothesis that ferric derisomaltose (FDI) would improve electron transport chain activity, given its high dependence on iron-sulfur clusters which facilitate electron transfer during oxidative phosphorylation.
Methods And Results: Vastus lateralis skeletal muscle biopsies were taken before and 2 weeks after randomization.
Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.
Eur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.